Literature DB >> 25535041

Determining the Cost-Savings Threshold for HIV Adherence Intervention Studies for Persons with Serious Mental Illness and HIV.

Evan S Wu1, Aileen Rothbard1,2,3, David R Holtgrave4, Michael B Blank5,6,7.   

Abstract

Persons with serious mental illnesses are at increased risk for contracting and transmitting HIV and often have poor adherence to medication regimens. Determining the economic feasibility of different HIV adherence interventions among individuals with HIV and serious mental illness is important for program planners who must make resource allocation decisions. The goal of this study was to provide a methodology to estimate potential cost savings from an HIV medication adherence intervention program for a new study population, using data from prior published studies. The novelty of this approach is the way CD4 count data was used as a biological marker to estimate costs averted by greater adherence to anti-retroviral treatment. Our approach is meant to be used in other adherence intervention studies requiring cost modeling.

Entities:  

Keywords:  HIV/AIDS; Health expenditures; Serious mental illness

Mesh:

Substances:

Year:  2014        PMID: 25535041      PMCID: PMC4478285          DOI: 10.1007/s10597-014-9788-6

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  40 in total

1.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

2.  HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.

Authors:  Davide Gibellini; Marco Borderi; Elisa De Crignis; Ronny Cicola; Laura Cimatti; Francesca Vitone; Francesco Chiodo; Maria Carla Re
Journal:  J Infect       Date:  2008-02-13       Impact factor: 6.072

3.  Revised cost estimates of Medicaid recipients with serious mental illness and HIV-AIDS.

Authors:  Aileen B Rothbard; Kay Miller; Sungeun Lee; Michael Blank
Journal:  Psychiatr Serv       Date:  2009-07       Impact factor: 3.084

4.  The cost effectiveness of combination antiretroviral therapy for HIV disease.

Authors:  K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  A randomized trial of a nursing intervention for HIV disease management among persons with serious mental illness.

Authors:  Michael B Blank; Nancy P Hanrahan; Martin Fishbein; Evan S Wu; Julie A Tennille; Thomas R Ten Have; Ann M Kutney-Lee; Robert Gross; Janet M Hines; James C Coyne; Linda H Aiken
Journal:  Psychiatr Serv       Date:  2011-11       Impact factor: 3.084

Review 6.  Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.

Authors:  Jessica E Hart; Christie Y Jeon; Louise C Ivers; Heidi L Behforouz; Adolfo Caldas; Peter C Drobac; Sonya S Shin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

7.  Costs of HIV medical care in the era of highly active antiretroviral therapy.

Authors:  K A Gebo; R E Chaisson; J G Folkemer; J G Bartlett; R D Moore
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

8.  The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection.

Authors:  H B Krentz; M C Auld; M J Gill
Journal:  HIV Med       Date:  2004-03       Impact factor: 3.180

Review 9.  The impact of mental health and substance abuse factors on HIV prevention and treatment.

Authors:  James Walkup; Michael B Blank; Jeffrey S Gonzalez; Steven Safren; Rebecca Schwartz; Larry Brown; Ira Wilson; Amy Knowlton; Frank Lombard; Cynthia Grossman; Karen Lyda; Joseph E Schumacher
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

10.  Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing.

Authors:  David R Holtgrave
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

View more
  1 in total

Review 1.  Primary and Secondary HIV Prevention Among Persons with Severe Mental Illness: Recent Findings.

Authors:  Andréa L Hobkirk; Sheri L Towe; Ryan Lion; Christina S Meade
Journal:  Curr HIV/AIDS Rep       Date:  2015-12       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.